What are the recommended glucocorticoid treatment guidelines, including dosing and monitoring, for patients with Duchenne muscular dystrophy?

Glucocorticoid Treatment in Duchenne Muscular Dystrophy

Daily glucocorticoid therapy with prednisone 0.75 mg/kg/day or deflazacort 0.9 mg/kg/day should be initiated when boys with DMD reach a functional plateau or decline, typically around age 4-6 years, and continued lifelong—even after loss of ambulation—to preserve motor function, delay respiratory decline, prevent scoliosis, and slow cardiomyopathy progression. 1, 2, 3

When to Initiate Treatment

Start glucocorticoids based on functional status, not arbitrary age cutoffs:

• Age 4-6 years at plateau or decline: Initiation highly recommended 1
• Age <4 years and improving: Do not start; monitor closely 1
• Age <4 years with plateau/decline: Consider alternative diagnoses first 1
• Complete immunization schedule before starting 1

The most recent high-quality RCT (2022, n=196) definitively demonstrated that daily regimens are superior to intermittent dosing for the composite outcome of motor function, pulmonary function, and treatment satisfaction over 3 years 3. This settles the long-standing debate about dosing schedules.

First-Line Dosing Regimens

Choose between two equally effective daily options:

Prednisone (First-line default)

• 0.75 mg/kg/day 1, 2, 3
• Maximum dose: 30-40 mg/day (cap at 40 kg body weight) 1

Deflazacort (First-line when weight/behavior concerns exist)

• 0.9 mg/kg/day 1, 2, 3
• Maximum dose: 36-39 mg/day (cap at 40 kg body weight) 1

The 2022 FOR-DMD trial found no significant difference in efficacy between daily prednisone and daily deflazacort 3, though deflazacort may cause less weight gain (very low quality evidence) 4 but carries higher cataract risk 2.

Dosing Adjustments Over Time

Increase dose incrementally with growth until reaching maximum weight of 40 kg, then maintain absolute dose 1. For non-ambulatory patients >40 kg, allow dose to drift down to 0.3-0.6 mg/kg/day range, which still provides substantial benefit 1.

If functional decline occurs on suboptimal dosing: Increase to target dose and reassess in 2-3 months 1.

Minimum effective dose: 0.3 mg/kg/day prednisone shows some benefit, though not maximal 1.

Alternative Regimens (Only if Daily Regimen Fails)

Use these ONLY when side effects from daily dosing are unmanageable:

1. Reduce daily dose by 25-33% and reassess in 1 month 1
2. If still intolerable:
   • Weekend-only prednisone: 5 mg/kg each Friday and Saturday 1, 2
   • Alternate-day: 0.75-1.25 mg/kg prednisone every other day (less effective) 1
   • Intermittent 10/10 or 10/20: Last resort before abandoning treatment 1

Critical caveat: The 2022 FOR-DMD trial showed intermittent prednisone (10 days on/10 days off) was significantly inferior to daily regimens 3. The 2016 AAN guideline found weekend-only dosing equivalent to daily over 12 months 2, but long-term data are lacking and non-randomized studies suggest daily regimens maintain superiority beyond one year 4.

Continue Treatment After Loss of Ambulation

Do not stop glucocorticoids when boys become wheelchair-dependent. Continuation provides critical benefits 1:

• Retards scoliosis progression
• Stabilizes pulmonary function decline
• Delays cardiomyopathy onset
• May reduce cardiac-related mortality

Recent 2024 data from 112 adults with DMD confirmed that glucocorticoids after loss of ambulation preserve late-stage functional abilities, respiratory function (delayed FVC <30% and <1L), and cardiac function (lower frequency of LVEF <50%) 5.

Side Effect Management Algorithm

Monitor proactively at every 6-month visit 1:

Weight Gain/Cushingoid Features

• If main concern: Switch to deflazacort or weekend-only regimen 1
• Deflazacort causes less weight gain than prednisone at 12 months (very low quality evidence) 4

Behavioral Issues (hyperactivity, emotional lability)

• Administer medication in afternoon after school 1
• If persistent: Consider deflazacort or weekend-only regimen 1

Growth Suppression

• Expected: 72% develop short stature on long-term daily therapy 6
• Weekend-only regimen shows greater linear height increase than daily 2, 4

Bone Health

• Asymptomatic vertebral compression fractures occur in 76% on long-term daily therapy 6
• Long bone fractures in 30% 6
• Monitor with DEXA scans; provide calcium/vitamin D supplementation 1

Cataracts

• 19% develop asymptomatic cataracts on long-term deflazacort 6
• Higher risk with deflazacort than prednisone 2
• Annual ophthalmologic screening required

If Side Effects Become Intolerable

Follow this stepwise approach 1:

1. Reduce daily dose by 25-33%, reassess in 1 month
2. If still intolerable, reduce another 25% (minimum 0.3 mg/kg/day)
3. If weight/behavior are primary issues, switch to deflazacort or weekend-only
4. If family about to abandon treatment entirely, use 10/10 or 10/20 intermittent schedule as last resort

Critical Practice Points

• Provide steroid emergency card listing considerations for acute illness, fracture, infection, surgery, or anesthesia 1
• Higher doses (1.5 mg/kg/day) are no more effective than 0.75 mg/kg/day 1
• Daily regimens are definitively superior to intermittent regimens based on the highest quality 2022 RCT 3
• Benefits extend well beyond ambulation: respiratory, cardiac, and orthopedic outcomes all improve with continued treatment 1, 5
• Side effects are common but generally manageable with proactive monitoring and dose adjustments 6

The evidence strongly supports lifelong daily glucocorticoid therapy as standard of care, with the 2022 FOR-DMD trial providing the most robust data to date that daily prednisone and daily deflazacort are equivalent and superior to intermittent dosing 3.